Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials
NCT ID: NCT00828919
Last Updated: 2024-12-03
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
52 participants
INTERVENTIONAL
2003-03-07
2023-08-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment
Patients continue the same treatment (axitinib monotherapy or in combination with crizotinib) as in prior axitinib study
axitinib
BID oral tablets. dose of axitinib (AG 013736) will be the same as they were taking in the previous trial
crizotinib
BID oral Capsules. Dose of crizotinib will be the same taken in previous axitinib trial.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
axitinib
BID oral tablets. dose of axitinib (AG 013736) will be the same as they were taking in the previous trial
crizotinib
BID oral Capsules. Dose of crizotinib will be the same taken in previous axitinib trial.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who were receiving axitinib (AG-013736) tablets at the time their previous trial ended
* Patients who have stable (SD) or responding disease (PR or CR) documented by the appropriate radiological, clinical, or laboratory assessments within 12 weeks before enrollment (Note: response criteria from the previous axitinib (AG-013736) protocol should be used to determine stable or responding disease).
* Patients who have progressive disease (PD) but have experienced "clinical benefit" as defined in the study protocol
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UC Irvine Medical Center
Orange, California, United States
University of California Irvine Medical Center - Chao Family Comprehensive Cancer Center
Orange, California, United States
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States
UCLA Hematology-Oncology-Santa Monica
Santa Monica, California, United States
University of Chicago Hospitals
Chicago, Illinois, United States
Johns Hopkins University
Baltimore, Maryland, United States
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, United States
University of Michigan Health System
Ann Arbor, Michigan, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Memorial Sloan-Kettering Cancer Center
New York, New York, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
The Cleveland Clinic
Cleveland, Ohio, United States
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
The University of Texas M.D. Anderson Cancer Center
Houston, Texas, United States
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Providence Regional Medical Center Everett - Providence Regional Cancer Partnership
Everett, Washington, United States
Providence Regional Medical Center Everett
Everett, Washington, United States
University of Wisconsin - Hospital and Clinics
Madison, Wisconsin, United States
Fakultni nemocnice Olomouc
Olomouc, Czech Republic, Czechia
Nemocnice Na Bulovce
Prague, , Czechia
Hopital de la Pitie Salpetriere
Paris, , France
Charité - Universitaetsmedizin Berlin, Charité Campus Mitte
Berlin, , Germany
Semmelweis Egyetem Altalanos Orvostudomanyi Kar
Budapest, , Hungary
Fondazione IRCCS, Istituto Nazionale Tumori, Laboratorio
Milan, , Italy
Fondazione IRCCS, Istituto Nazionale Tumori, S.S.D Oncologia Medica dei Tumori testa-collo
Milan, , Italy
National Cancer Center Hospital East
Kashiwa, Chiba, Japan
Kinki University Hospital
Sayama, Osaka, Japan
Chiba Cancer Center
Chiba, , Japan
Kyushu University Hospital
Fukuoka, , Japan
Nagasaki University Hospital
Nagasaki, , Japan
FSBSI "N.N. Blokhin Russian Cancer Research Center"
Moscow, Russian Federation, Russia
Samsung Medical Center
Seoul, , South Korea
Taichung Veterans General Hospital
Taichung, , Taiwan
Nottingham City Hospital / Oncology Department
Nottingham, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2005-000051-15
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
A4061008
Identifier Type: -
Identifier Source: org_study_id